Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma

NCT07276724 is registered in ClinicalTrials.gov with Generate Biomedicines as lead sponsor.

NCT NCT07276724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07276724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma
Lead sponsor
Generate Biomedicines
Phase
Phase 3
Overall status
Recruiting
Start date
December 3, 2025
Completion date
December 31, 2028
Enrollment
786 (estimated)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma